Clinical Study
Eye (2004) 18, 893–899. doi:10.1038/sj.eye.6701345 Published online 27 February 2004
Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma
Clinical sites were supported by a grant from Pharmacia Hellas, Greece. Pharmaceutical Research Network, LLC received no clinical funding for this study.
A G P Konstas1, N Mylopoulos2, C H Karabatsas3, V P Kozobolis4, S Diafas5, P Papapanos6, N Georgiadis1 and W C Stewart7,8
- 1University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece
- 2Private Practice, Thessaloniki, Greece
- 3University Department of Ophthalmology, Larissa, Greece
- 4University Department of Ophthalmology, Alexandroupolis, Greece
- 5Papageorgiou General Hospital, Thessaloniki, Greece
- 6Prefectural Hospital of Korinthos, Korinthos, Greece
- 7Pharmaceutical Research Network, LLC Charleston, SC, USA
- 8Carolina Eye Institute at the University of South Carolina, School of Medicine Columbia, SC, USA
Correspondence: WC Stewart MD, Pharmaceutical Research Network, LLC 1639 Tatum Street Charleston, SC 29412, USA. Tel: +843 762 6500; Fax: +843 762 7444; E-mail: prnc@bellsouth.net
Received 15 April 2003; Accepted 10 October 2003; Published online 27 February 2004.
Abstract
Aims To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vslatanoprost in subjects with exfoliation glaucoma (XFG).
Methods A 3-month prospective, single-masked, active-controlled, parallel comparison performed in six centres in Greece that randomized subjects in a 1 : 1 ratio to either latanoprost in the evening (2000 hours) and placebo in the morning (0800 hours), or timolol twice daily (0800 and 2000 hours).
Results In all, 103 subjects completed the study. After 3 months of chronic dosing, the latanoprost group exhibited a trend to a greater diurnal IOP reduction from an untreated baseline (24.9
3.2–17.42.9) compared with timolol (24.72.8–18.31.9 mmHg) (P=0.07). Latanoprost showed a significantly greater IOP reduction at 0800 hours (-8.5 vs-6.0 mm Hg for timolol, P<0.0001) whereas no difference was observed between the two medications at 1000, 1400, and 2000 hours after a Bonferroni Correction. In addition, latanoprost demonstrated a narrower range of diurnal IOP (2.4) than timolol (3.2 mmHg)(P=0.0017). Safety was similar between groups, except there was more conjunctival hyperaemia with latanoprost (n=8) than timolol (n=1)(P=0.01).
Conclusions This study suggests that latanoprost provides a statistically lower 08:00-hour IOP and better range of IOP than timolol in the treatment of XFG glaucoma.
Keywords:
latanoprost, timolol, exfoliation glaucoma
